Larry Mathis Financial Planning LLC Buys Shares of 2,100 Elevance Health, Inc. $ELV

Posted by Brian Himes on Jun 20th, 2026

Larry Mathis Financial Planning LLC bought a new stake in shares of Elevance Health, Inc. (NYSE:ELV – Free Report) in the fourth quarter, Holdings Channel.com reports. The firm bought 2,100 shares of the company’s stock, valued at approximately $736,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of the company. Corient Private Wealth LLC boosted its position in shares of Elevance Health by 12.2% during the 4th quarter. Corient Private Wealth LLC now owns 67,261 shares of the company’s stock valued at $23,579,000 after purchasing an additional 7,315 shares in the last quarter. Storen Legacy Partners LLC bought a new stake in shares of Elevance Health in the 4th quarter worth approximately $207,000. Pure Financial Advisors LLC lifted its stake in Elevance Health by 10.3% during the fourth quarter. Pure Financial Advisors LLC now owns 2,975 shares of the company’s stock valued at $1,043,000 after purchasing an additional 277 shares during the last quarter. Reflection Asset Management bought a new stake in Elevance Health during the fourth quarter worth approximately $94,000. Finally, Tobam boosted its holdings in Elevance Health by 5.3% during the fourth quarter. Tobam now owns 7,627 shares of the company’s stock worth $2,674,000 after buying an additional 383 shares in the last quarter. Institutional investors own 89.24% of the company’s stock.

Insider Activity

In related news, Director Robert L. Dixon, Jr. sold 151 shares of Elevance Health stock in a transaction dated Thursday, June 11th. The stock was sold at an average price of $401.77, for a total transaction of $60,667.27. Following the sale, the director directly owned 10,734 shares of the company’s stock, valued at $4,312,599.18. This trade represents a 1.39% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 0.34% of the company’s stock.

Elevance Health Stock Up 0.1%

Elevance Health stock opened at $388.77 on Friday. The company has a current ratio of 1.48, a quick ratio of 1.48 and a debt-to-equity ratio of 0.70. Elevance Health, Inc. has a 1-year low of $273.71 and a 1-year high of $426.98. The firm’s fifty day simple moving average is $375.30 and its 200-day simple moving average is $346.91. The company has a market capitalization of $84.43 billion, a P/E ratio of 16.54, a P/E/G ratio of 2.20 and a beta of 0.67.

Elevance Health (NYSE:ELV – Get Free Report) last posted its earnings results on Wednesday, April 22nd. The company reported $12.58 earnings per share for the quarter, topping the consensus estimate of $10.74 by $1.84. The firm had revenue of $49.49 billion during the quarter, compared to analyst estimates of $48.21 billion. Elevance Health had a return on equity of 15.58% and a net margin of 2.62%.The company’s revenue for the quarter was up 1.5% on a year-over-year basis. During the same period in the previous year, the company earned $11.97 EPS. Elevance Health has set its FY 2026 guidance at 19.850- EPS. Sell-side analysts forecast that Elevance Health, Inc. will post 26.93 earnings per share for the current fiscal year.

Elevance Health Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, June 25th. Stockholders of record on Wednesday, June 10th will be issued a dividend of $1.72 per share. The ex-dividend date is Wednesday, June 10th. This represents a $6.88 annualized dividend and a dividend yield of 1.8%. Elevance Health’s payout ratio is presently 29.26%.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on ELV shares. Sanford C. Bernstein boosted their target price on Elevance Health from $384.00 to $424.00 and gave the stock an “outperform” rating in a research report on Friday, April 24th. Truist Financial lifted their price target on Elevance Health from $375.00 to $450.00 and gave the stock a “buy” rating in a research note on Monday, June 1st. JPMorgan Chase & Co. boosted their price objective on Elevance Health from $411.00 to $476.00 and gave the stock an “overweight” rating in a report on Monday, June 8th. Morgan Stanley upped their price objective on shares of Elevance Health from $352.00 to $404.00 and gave the company an “equal weight” rating in a research note on Thursday, June 4th. Finally, Evercore reissued a “hold” rating on shares of Elevance Health in a research report on Tuesday, May 19th. Fourteen research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $416.11.

Get Our Latest Research Report on ELV

About Elevance Health

(Free Report)

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.